Back to Search Start Over

FRI0054 A novel pharmacological action of MTX through circadian clock genes in RA fibroblast-like synovial cells

Authors :
Naonori Hashimoto
N Nakagawa
Kenta Kaneshiro
Ayako Nakai
Kohjin Suzuki
Yoshitada Sakai
Kohsuke Yoshida
Akira Hashiramoto
Yoshiko Kawasaki
Teppei Hashimoto
Nao Shibanuma
Source :
Poster Presentations.
Publication Year :
2017
Publisher :
BMJ Publishing Group Ltd and European League Against Rheumatism, 2017.

Abstract

Background Methotrexate inhibits the proliferation of RA fibroblast-like synovial cells (RA-FLS) by folate anti-metabolism. We previously reported that disruptions of circadian clock genes were involved in the pathogenesis of inflammatory arthritis (1,2). Objectives To explore pharmacological effects of MTX on circadian clock genes of RA-FLS. Methods Under treatments of MTX on RA-FLS, cell viabilities were determined by WST-8 assay, expressions of circadian clock genes (Clock, Bmal1, Cry1 and Per2), circadian transcriptional factor PAR bZip (Dbp, Tef and Hlf), and pro-apoptotic Bcl-2 interacting killer (BIK) were examined by real time PCR, and expressions of PER2 and CYTOCHROME C were examined by western blotting. The expressions of PER2, BIK, CYTOCHROME C and morphological changes of the nucleus were observed by fluorescent immunostaining. RA-FLS were transfected with Per2 and BIK siRNAs and successively treated with MTX to determine cell viabilities by WST-8 assay. Results MTX (1,10 nM) treatment significantly decreased the cell viabilities. MTX (10nM) have increased mRNA expression of Per2, Dbp, Tef, Hlf, and BIK, and protein expressions of PER2 and CYTOCHROME C, as well. In fluorescent observations, PER2, BIK, and CYTOCHROME C were increased in apoptotic cells. Cytotoxicity of MTX was attenuated by knockdowns of Per2 or BIK in RA-FLS. Conclusions The transcriptional factor PAR bZip binds to the D-box elements of Per2 and BIK promoters (3,4). Here, we propose a novel action of MTX that up-regulates the expressions of Per2 and BIK via PAR bZip to induce apoptosis in RA-FLS. References Hashiramoto A, J Immunol. 2010 Feb 1;184(3):1560–5. Hand LE, FASEB J. 2016 Nov;30(11):3759–3770. Yoshida K, Scand J Rheumatol. 2013;42(4):276–80. Ritchie A, Cell Death Differ. 2009 Jun;16(6):838–46. Disclosure of Interest None declared

Details

Database :
OpenAIRE
Journal :
Poster Presentations
Accession number :
edsair.doi...........daafe292774ae0723d80b2a94577939e
Full Text :
https://doi.org/10.1136/annrheumdis-2017-eular.3351